Linderalactone 是从Lindera aggregata中分离出来的一种重要的倍半萜烯内酯。Linderalactone 通过调节凋亡相关蛋白的表达和抑制 JAK/STAT 信号通路来抑制癌细胞生长。Linderalactone 还以IC50值为 15 μM 来抑制肺癌 A-549 细胞的增殖。
| 生物活性 | Linderalactone is an important sesquiterpene lactone isolated fromLindera aggregata. Linderalactone inhibitscancergrowth by modulating the expression ofapoptosis-related proteins and inhibition of JAK/STAT signalling pathway. Linderalactone also inhibits the proliferation of the lungcancerA-549 cells with anIC50of 15 μM[1][2]. |
体外研究
(In Vitro) | Linderalactone (0-100 μM; 24 hours; A549 cells) treatment inhibits the growth of A549 cells concentration-dependently. TheIC50of linderalactone is 15 μM[1].
Linderalactone (7.5-30 μM; A549 cells) treatment induces apoptosis in A549 cells in a dose-dependent manner[1].
Linderalactone (7.5-30 μM; 24 hours; A549 cells) treatment induces G2/M cell cycle arrest of A549 cells dose-dependently[1].
Linderalactone (7.5-30 μM; A549 cells) inhibits the expression of STAT1, JAK1 and JAK2. Linderalactone could also inhibit the phosphorylation of pSTAT1, pSTAT-2, pJAK1 and pJAk2[1].
Cell Viability Assay[1] | Cell Line: | Lung cancer A549 cells | | Concentration: | 0 μM, 1.6 μM, 3.2 μM, 6.25 μM, 12.5 μM, 25 μM, 50 μM, 100 μM | | Incubation Time: | 24 hours | | Result: | Inhibited the growth of A549 cells concentration-dependently. |
Apoptosis Analysis[1] | Cell Line: | Lung cancer A549 cells | | Concentration: | 7.5 μM, 15 μM, 30 μM | | Incubation Time: | | | Result: | Induced apoptosis in A549 cells in a dose-dependent manner. |
Cell Cycle Analysis[1] | Cell Line: | Lung cancer A549 cells | | Concentration: | 7.5 μM, 15 μM, 30 μM | | Incubation Time: | 24 hours | | Result: | Induced G2/M cell cycle arrest. |
Western Blot Analysis[1] | Cell Line: | Lung cancer A549 cells | | Concentration: | 7.5 μM, 15 μM, 30 μM | | Incubation Time: | | | Result: | Inhibited the JAK/STAT pathway in A549 cells. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 结构分类 | |
| 来源 | - Plants
- Lauraceae
- Lindera aggregata(Sims) Kosterm.
|
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | -20°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| 溶解性数据 | In Vitro: DMSO : 33.33 mg/mL(136.44 mM;Need ultrasonic) 配制储备液 | 1 mM | 4.0935 mL | 20.4675 mL | 40.9350 mL | | 5 mM | 0.8187 mL | 4.0935 mL | 8.1870 mL | | 10 mM | 0.4093 mL | 2.0467 mL | 4.0935 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (protect from light)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: 2.5 mg/mL (10.23 mM); Suspended solution; Need ultrasonic
此方案可获得 2.5 mg/mL (10.23 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。 2. 请依序添加每种溶剂： 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (10.23 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (10.23 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
*以上所有助溶剂都可在本网站选购。 |
m.cnreagent.com